Financial Performance - Revenue for the year ended December 31, 2025, was $1,142,000, representing an increase of $1,034,000 or 957% compared to $108,000 in 2024, primarily due to revenue from the acquisition of Evoke Neuroscience [424]. - Cost of goods sold for 2025 was $497,000, up from $0 in 2024, with manufacturing and inventory costs accounting for 43% of the increase and labor costs for 33% [425]. - Research and development expenses decreased by $472,000 or 24% to $1,482,000 in 2025, primarily due to equity vesting related to the merger in August 2024 [426]. - Selling and marketing expenses decreased by $401,000 or 33% to $800,000 in 2025, mainly due to reduced consultant use following a rebranding in 2024 [427]. - General and administration expenses increased by $835,000 or 13% to $6,968,000 in 2025, largely due to higher directors and officers insurance costs and accrued fees from the cancellation of the Equity Line of Credit [428]. - The company reported an operating loss of $8,856,000 for 2025, an improvement of $1,198,000 compared to a loss of $10,054,000 in 2024 [422]. - Net cash used in operating activities was $8,194,000 for 2025, an increase of $2,039,000 or 33% from $6,155,000 in 2024, driven by higher operating costs and research and development expenses [441]. - Net cash used in investing activities rose to $2,488,000 in 2025 from $477,000 in 2024, representing a 422% increase attributed to the acquisition of Evoke Neuroscience [442]. - As of December 31, 2025, the company had an accumulated deficit of $111,615,000 and negative cash flows from operating activities of $8,194,000, raising substantial doubt about its ability to continue as a going concern [431]. Acquisitions and Investments - The company acquired all outstanding stock of Evoke for approximately $6,000, consisting of $3,000 in cash and 857,142 shares of Common Stock valued at $3.50 per share [374]. - The acquisition of Evoke Neuroscience was completed for a total consideration of $6,221, including $3,000 in cash and 857,142 shares of common stock [401]. - The company raised $150,000 through warrant exercises and $2,250,000 through a private placement after December 31, 2025, with investors having the right to purchase up to an additional $18,000,000 of units [420]. Revenue Model and Business Strategy - The company has a subscription-based commercial model that creates a recurring revenue stream, scaling with clinical utilization [360]. - The company plans to generate revenue through healthcare professionals in the U.S. and collaborations with pharmaceutical companies for neuroscience drug development [392]. Clinical Operations - The Evoke System is actively used across more than 85 clinical sites in the United States as of December 31, 2025, enhancing clinical decision-making through EEG and ERP assessments [360]. - The Firefly Platform integrates hardware, software, and data infrastructure to enhance the quality of electrophysiological assessments in clinical settings [359]. Stock and Warrants - The company generated total proceeds of $8,825 from the exercise of warrants to purchase 1,623,530 shares of Common Stock at various exercise prices [362]. - On March 28, 2025, the company issued 547,737 units at a purchase price of $3.00 per unit, each consisting of one share of Common Stock or a prefunded warrant [363]. - The company issued 400,000 units at a total purchase price of $1,200 on June 16, 2025, with each unit priced at $3.00 [375]. - The company entered into a warrants cancellation and exchange agreement, resulting in the exchange of June 2025 Warrants for New 2025 Warrants to purchase 800,000 shares of Common Stock at an exercise price of $0.50 per share [382]. - The company entered into an At the Market Offering Agreement with Konik Capital Partners, allowing for the sale of up to $7,434,266 in Common Stock [383]. - The March 2026 Purchase Agreement involves the issuance of up to 13,500,000 units at a price of $1.50 per unit, with an initial investment of $2,250,000 from accredited investors [388]. - The company will pay Konik a commission of 2.0% on gross proceeds from ATM Shares sold, along with reimbursement for legal fees not exceeding $50,000 [387]. - The offering was structured to comply with Nasdaq Listing Rule 5635(d) without requiring stockholder approval [390]. - The company will file a registration statement on Form S-1 for the resale of shares and warrant shares by April 15, 2026 [390]. Impairments and Market Conditions - No goodwill impairment was recognized as the market capitalization exceeded net assets, with a share price recovery to $1.73 by March 11, 2026 [406]. - Total impairment recognized on pre-acquisition Firefly assets was $251, due to the discontinuation of the BNA software platform and Zeto headsets [409]. - No applicable market risk disclosures were provided in the document [448].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Artelo Biosciences, Inc. (ARTL) increased by 134% to $7.48 - Onconetix, Inc. (ONCO) rose by 64% to $5.28 - Robin Energy Ltd. (RBNE) gained 23% to $2.62 - Legence Corp. (LGN) up by 13% to $60.10 - Unity Software Inc. (U) increased by 13% to $19.38 - Battalion Oil Corporation (BATL) also rose by 13% to $6.30 - SIGA Technologies, Inc. (SIGA) up by 11% to $5.55 - Argan, Inc. (AGX) increased by 9% to $451.85 - Greenland Energy Company Common Stock (GLND) rose by 9% to $14.25 - AleAnna, Inc. (ANNA) gained 8% to $7.70 [3] Premarket Losers - Datacentrex, Inc. (DTCX) decreased by 28% to $2.21 - EpicQuest Education Group International Limited (EEIQ) fell by 20% to $6.70 - Fitness Champs Holdings Limited (FCHL) down by 18% to $2.90 - ENDRA Life Sciences Inc. (NDRA) decreased by 11% to $4.05 - Zenas BioPharma, Inc. (ZBIO) down by 9% to $20.11 - Armata Pharmaceuticals, Inc. (ARMP) fell by 9% to $8.50 - Firefly Neuroscience, Inc. (AIFF) decreased by 8% to $2.77 - Lithium Argentina AG (LAR) down by 7% to $6.34 - MKDWELL Tech Inc. (MKDW) decreased by 6% to $7.30 - Upstream Bio, Inc. (UPB) fell by 5% to $9.23 [4]

Core Insights - Firefly shares have experienced a significant increase, trading 38.69% higher at $2.33, indicating strong market confidence in the company's prospects [5] Group 1: Partnership and Expansion - Firefly has established a partnership with the Department of Defense to support the assessment and treatment of U.S. service members and veterans suffering from post-traumatic stress disorder and traumatic brain injury [2] - This partnership expands Firefly's commercial footprint into the U.S. government and defense health sectors, potentially serving as a significant channel for the company's broader commercial strategy [4] - The CEO, Greg Lipschitz, emphasized that the strategic partnership positions the company to benefit from the growing U.S. government investment in military brain health, leveraging its validated, FDA-cleared platform [4] Group 2: Technology Deployment - The company's FDA 510(k)-cleared, AI-powered EEG/ERP platform is being deployed across related Department of Defense programs, providing healthcare providers with objective neurological data for diagnosis, treatment planning, and outcomes tracking [3] - The platform is designed to be non-invasive and scalable across both clinical and operational environments, enhancing its applicability in various settings [3]

Core Insights - Firefly Neuroscience, Inc. has announced a partnership with the Department of War to support the assessment and treatment of PTSD and TBI among U.S. service members and veterans, marking a significant expansion into the U.S. government and defense health sectors [1][5] Industry Context - PTSD and TBI are major health challenges for the U.S. military, with the economic burden of PTSD estimated at $232.2 billion, of which $42.7 billion is attributed to the military population [3] - The incidence of TBI is notably higher in military personnel compared to civilians, with over 444,300 service members diagnosed with at least one TBI from 2000 to 2021 [3][4] Company Technology - Firefly's FDA-cleared, AI-powered EEG/ERP platform is designed to provide military healthcare providers with objective neurological data for precise diagnosis and individualized treatment planning [5][6] - The technology is non-invasive and scalable, suitable for both clinical and operational environments, and aims to fill the gap in objective diagnostic tools for military mental health [4][5] Strategic Positioning - The partnership with the Department of War is expected to enhance Firefly's commercial strategy by expanding its footprint in the U.S. government and defense health sectors [5][6] - The company aims to leverage its growing repository of brain scan data and NVIDIA GPU acceleration to develop a proprietary foundation model of the human brain [6]

Core Insights - Firefly Neuroscience, Inc. is advancing research to identify ADHD subtypes using AI-powered EEG/ERP technology, which may enhance treatment personalization and monitoring [1][4][5] - The ADHD treatment market in the U.S. is estimated to exceed $10 billion, highlighting the significant unmet needs in accurate diagnosis and treatment [1] - Firefly's platform is based on a growing database of over 191,000 brain scans, aiming to create the world's first EEG/ERP brain foundation model [1][5] Company Developments - Firefly's technology aims to distinguish between the three main ADHD subtypes: hyperactive and impulsive, inattentive, and combined, which could lead to more effective treatment strategies [1][4] - The company has received FDA-510(k) clearance for its Evoke System, which is integral to its research and development efforts [1] - Firefly's Chief Technology Officer emphasized the potential for personalized treatment recommendations based on subtype-specific biomarker profiles [4] Industry Context - Current ADHD diagnoses rely heavily on subjective symptom checklists and the DSM-5-TR criteria, which may not adequately address the nuances of the disorder [2][3] - The introduction of objective biological markers for ADHD could revolutionize the clinical approach to treatment, improving outcomes for patients [1][4] - The use of AI and EEG/ERP technology in neuroscience is positioned to transform diagnostic and treatment monitoring methods for various neurological and mental health conditions [5]

Core Insights - Firefly Neuroscience Inc. is experiencing a significant increase in its stock price due to advancements in brain scan technologies and a notable expansion in its commercial operations [1] Group 1: Commercial Expansion - Firefly reported a 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes [2] - The company ended 2025 with partnerships with 99 commercial users, completing over 10,800 EEG/ERP brain scans, reflecting year-over-year increases of 1,880% in partner sites and 3,227% in clinical assessments [2] - Firefly's proprietary database now contains over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository [3] Group 2: Stock Performance - The stock is currently trading 103.6% above its 20-day simple moving average (SMA) and 18.1% above its 100-day SMA, indicating short-term strength [4] - Over the past 12 months, shares have decreased by 63.40%, and they are closer to their 52-week lows than highs [4] - Firefly Neuroscience shares were up 15.49% at $1.64, with key resistance at $2.00 and key support at $1.00 [6] Group 3: Technical Indicators - The RSI is at 72.82, indicating that the stock is in overbought territory, which may suggest a potential pullback [5] - The MACD is at 0.0411, above its signal line at -0.0517, indicating bullish momentum [5] - The combination of overbought RSI and bullish MACD suggests mixed momentum, indicating current strength but caution may be warranted due to the overbought condition [5]

Core Insights - Firefly Neuroscience Inc. is experiencing significant growth in its commercial operations and EEG/ERP brain scan volumes, indicating a strong market presence and demand for its services [2][3]. Group 1: Commercial Expansion - The company reported a 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes [2]. - By the end of 2025, Firefly established partnerships with 99 commercial users, completing over 10,800 EEG/ERP brain scans, which represents year-over-year increases of 1,880% in partner sites and 3,227% in clinical assessments [2]. Group 2: Data Repository and AI Capabilities - Firefly's proprietary database now contains over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository [3]. - This growth is anticipated to enhance the company's capabilities in AI-driven biomarker discovery and improve diagnostic methods for neurological conditions [3]. Group 3: Management Perspective - The CEO of Firefly, Greg Lipschitz, emphasized the importance of their growing clean data foundation and the deployment of NVIDIA L40S GPU acceleration for next-generation EEG/ERP processing, positioning the company for breakthroughs in cognitive brain biomarker discovery [4]. Group 4: Stock Performance - Firefly Neuroscience shares are currently trading 75.18% above their previous close, reflecting strong momentum, with a significant increase over the past 12 months [5]. - During premarket trading on Wednesday, shares rose over 60% to $1.10, indicating positive market sentiment [5].

Core Insights - Firefly Neuroscience, Inc. has achieved a greater than 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes, indicating significant growth in its operations and market presence [1][2] - The company ended 2025 with 99 commercial partners, completing over 10,800 EEG/ERP brain scans, reflecting year-over-year growth of 1,880% in partner sites and 3,227% in clinical assessments since the end of 2024 [2] - Firefly aims to leverage AI and EEG/ERP technology to transform neuroscience and clinical development, with a focus on cognitive brain biomarker discovery [3] Company Overview - Firefly is an AI company focused on developing innovative solutions to enhance brain health outcomes for patients with neurological and mental disorders [1] - The company possesses the world's largest standardized EEG/ERP repository, with over 191,000 brain scans, which supports its advanced analytics technology [4] - Firefly's technology is FDA-510(k)-cleared and has the potential to revolutionize diagnostic and treatment monitoring methods for various conditions, including depression and ADHD [4]

Core Insights - Firefly Neuroscience, Inc. reported significant financial growth in Q3-2025, with revenues increasing over tenfold year-over-year and 30% sequentially, primarily due to the acquisition of Evoke Neuroscience [4][7] - The company successfully integrated the Evoke business, leading to a 10.9% increase in EEG/ERP scan volumes quarter-over-quarter [3][7] - Operating expenses decreased by 35% year-over-year, contributing to a reduced net loss of $2.6 million, a 38% improvement compared to the same period in 2024 [5][6][7] Financial Performance - Q3-2025 revenue reached $388,000, up from $33,000 in Q3-2024, and a sequential increase from $299,000 in Q2-2025 [4][7] - Total operating expenses for Q3-2025 were approximately $2.8 million, down from $4.3 million in the prior year [5][7] - The net loss for Q3-2025 was approximately $2.6 million, or $0.20 per share, compared to a net loss of $4.3 million, or $0.61 per share, in Q3-2024 [6][7] Business Developments - The company is focused on executing its commercial growth strategy while leveraging NVIDIA's advanced software for developing EEG/ERP-based models of the human brain [3] - Firefly launched the 'CLEAR' platform for EEG data quality enhancement, developed using NVIDIA's L40S GPU [7] - A partnership with HealingMaps was established to provide cognitive electrophysiology analytics to over 2,500 clinics across North America [7] Cash Position - As of the end of Q3-2025, Firefly had cash reserves of $4.3 million [8]

Financial Performance - Firefly Neuroscience, Inc. reported a total revenue of $1,200,000 from the sale of 400,000 units at a price of $3.00 per unit in June 2025[117]. - Revenue for the three months ended September 30, 2025, was $388, compared to $33 for the same period in 2024, representing an increase of $355, or 1,076%[137]. - Revenue for the nine months ended September 30, 2025, was $730, compared to $55 for the same period in 2024, representing an increase of $675, or 1,227%[146]. - Other income for the three months ended September 30, 2025, was $17, compared to $(21) for the same period in 2024, representing an increase of $38, or 543%[144]. Expenses - Cost of goods sold for the three months ended September 30, 2025, was $242, up from $nil in the same period of 2024, reflecting Evoke product sales and related operating costs[138]. - Research and development expenses for the three months ended September 30, 2025, were $378, a decrease of $500, or 57%, compared to $878 for the same period in 2024[140]. - Selling and marketing expenses for the three months ended September 30, 2025, were $265, a decrease of $166, or 39%, compared to $431 for the same period in 2024[141]. - General and administration expenses for the three months ended September 30, 2025, were $2,007, a decrease of $985, or 33%, compared to $2,992 for the same period in 2024[142]. - Cost of goods sold for the nine months ended September 30, 2025, was $267, up from $nil in the same period of 2024, reflecting Evoke product sales and related operating costs[147]. - General and administration expenses for the nine months ended September 30, 2025, were $4,968, an increase of $785, or 19%, compared to $4,183 for the same period in 2024, primarily due to additional D&O insurance costs[150]. - Impairment expenses for the three months ended September 30, 2025, were $152, compared to $nil for the same period in 2024, representing an increase of $152[143]. Cash Flow - The company reported an accumulated deficit of $108,896 and negative cash flows from operating activities of $6,389 as of September 30, 2025[157]. - Net cash used in operating activities increased by $1,452, or 29%, to $6,389 for the nine months ended September 30, 2025, compared to $4,937 for the same period in 2024[162]. - Net cash used in investing activities surged by $2,064, or 515%, to $2,465 for the nine months ended September 30, 2025, primarily due to the acquisition of Evoke Neuroscience[163]. - Net cash provided from financing activities increased by $6,944, or 157%, to $11,369 for the nine months ended September 30, 2025, compared to $4,425 for the same period in 2024[164]. Acquisitions and Financing - The company acquired Evoke for approximately $6,000,000, consisting of $3,000,000 in cash and 857,142 shares valued at $3.50 per share[118]. - The company is increasingly reliant on machine learning models for EEG/ERP interpretation, with performance depending on training data diversity and ongoing monitoring[171]. - The company has no committed source of financing and may face challenges in raising funds as needed to continue operations[172]. - The company experienced a total of $8,825 in proceeds from the exercise of warrants to purchase 1,623,530 shares of common stock during the week of February 21, 2025[170]. Business Strategy and Operations - The company plans to generate revenue through a base service fee and per-use fee model for healthcare providers, and tailored models for pharmaceutical companies[112]. - Firefly's products are FDA-510(k) cleared, enhancing neurological assessments and enabling early detection of neurophysiological deviations[111]. - The company aims to improve patient outcomes by utilizing AI to analyze EEG data, potentially transforming brain health management[116]. - The sales team is focused on targeted outreach and client engagement to drive adoption of the platform in the medical community[112]. - The company emphasizes the importance of establishing an objective baseline measurement of brain function to optimize patient care[115]. - Firefly's business strategy includes collaborations with neuroscience drug development companies to support clinical strategies[112]. Risks and Challenges - The company faces risks including market volatility, regulatory challenges, and the ability to maintain sufficient funding for operations[106]. - Management has identified material weaknesses in internal controls over financial reporting, which are being addressed with a remediation plan projected for completion by Q1 2026[181].